Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Recruiting

Phase 1

TTF & Cabozantinib, Pembrolizumab, Nab-PaclitaxelPhase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05092373

Conditions

Advanced Breast Carcinoma

Advanced Endometrial Carcinoma

Advanced Fallopian Tube Carcinoma

Advanced Hepatocellular Carcinoma

Advanced Malignant Abdominal Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Cabozantinib S-malate

Nab-paclitaxel

Tumor Treating Fields Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-04-01.